Meeting
2019 ASCO Annual Meeting
Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study.
Presenter
Uday R. Popat, MD
The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Allogenic Stem Cell Transplantation
Clinical Trial Registration Number
NCT02861417
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7007)
DOI
10.1200/JCO.2019.37.15_suppl.7007
Abstract #
7007
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2015 Breast Cancer Symposium
Welcome
Speaker: Julie Gralow, MD
Videos & Slides
2013 ASCO Annual Meeting
Multi-institutional study of allogeneic bone marrow transplantation using myeloablative busulfan (Bu)/fludarabine (Flu) conditioning and short-course, single-agent graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy).
Speaker: Christopher George Kanakry, MD
Videos & Slides
2022 ASCO Annual Meeting
A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial.
Speaker: Yuk Ting Ma, PhD
Speaker: Panel Discussion